Compare DOMO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DOMO | MOLN |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 144.0M |
| IPO Year | 2018 | 2021 |
| Metric | DOMO | MOLN |
|---|---|---|
| Price | $3.69 | $3.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $10.28 | $8.38 |
| AVG Volume (30 Days) | ★ 692.6K | 2.0K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $2.39 | $3.41 |
| 52 Week High | $18.49 | $5.36 |
| Indicator | DOMO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 32.97 |
| Support Level | $3.34 | $3.52 |
| Resistance Level | $4.11 | $3.97 |
| Average True Range (ATR) | 0.24 | 0.09 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 49.32 | 3.70 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.